

## Publikationen von Prof. Dr. med. Stephan Kanzler



Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.

Haas M, Siveke JT, Schenk M, Lerch MM, Caca K, Freiberg-Richter J, Fischer von Weikersthal L, Kullmann F, Reinacher-Schick A, Fuchs M, **Kanzler S**, Kunzmann V, Ettrich TJ, Kruger S, Westphalen CB, Held S, Heinemann V, Boeck S.

Eur J Cancer. 2018 May;94:95-103.

Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801).

Stahl M, Maderer A, Lordick F, Mihaljevic AL, **Kanzler S**, Hoehler T, Thuss-Patience P, Mönig S, Kunzmann V, Schroll S, Sandermann A, Tannapfel A, Meyer HJ, Schuhmacher C, Wilke H, Moehler M; Arbeitsgemeinschaft Internistische Onkologie (AIO) Oesophageal and Gastric Cancer Working Group and the Chirurgische Arbeitsgemeinschaft Onkologie (CAOGI/DGAV) of the German Cancer Society.

Eur J Cancer. 2018 Apr;93:119-126.

Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.

Dietz J, Susser S, Vermehren J, Peiffer KH, Grammatikos G, Berger A, Ferenci P, Buti M, Müllhaupt B, Hunyady B, Hinrichsen H, Mauss S, Petersen J, Buggisch P, Felten G, Hüppe D, Knecht G, Lutz T, Schott E, Berg C, Spengler U, von Hahn T, Berg T, Zeuzem S, Sarrazin C; European HCV Resistance Study Group.

Gastroenterology. 2018 Mar;154(4):976-988.

Hepatocyte-specific Smad7 deletion accelerates DEN-induced HCC via activation of STAT3 signaling in mice.

Feng T, Dzieran J, Yuan X, Dropmann A, Maass T, Teufel A, Marhenke S, Gaiser T, Rückert F, Kleiter I, **Kanzler S**, Ebert MP, Vogel A, Ten Dijke P, Dooley S, Meindl-Beinker NM.

Oncogenesis. 2017 Jan 30;6(1):e294.

Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program.

Moehler M, Gepfner-Tuma I, Maderer A, Thuss-Patience PC, Ruessel J, Hegewisch-Becker S, Wilke H, Al-Batran SE, Rafiyan MR, Weißinger F, Schmoll HJ, Kullmann F, von Weikersthal LF, Siveke JT, Weusmann J, **Kanzler S**, Schimanski CC, Otte M, Schollenberger L, Koenig J, Galle PR.

BMC Cancer. 2016 Aug 31;16:699.

Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: A double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.

Moehler M, Maderer A, Schimanski C, **Kanzler S**, Denzer U, Kolligs FT, Ebert MP, Distelrath A, Geissler M, Trojan J, Schütz M, Berie L, Sauvigny C, Lammert F, Lohse A, Dollinger MM, Lindig U, Duerr EM, Lubomierski N, Zimmermann S, Wachtlin D, Kaiser AK, Schadmand-Fischer S, Galle PR, Woerns M; Working Group of Internal Oncology (AIO).

Eur J Cancer. 2014 Dec;50(18):3125-35. doi: 10.1016/j.ejca.2014.09.013. Epub 2014 Oct 15.

Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205.

Hoehler T, von Wichert G, Schimanski C, **Kanzler S**, Moehler MH, Hinke A, Seufferlein T, Siebler J, Hochhaus A, Arnold D, Hallek M, Hofheinz R, Hacker UT.

Br J Cancer. 2013 Sep 17;109(6):1408-13.

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.

Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, **Kanzler S**, Götte H, Melezinková H, Moehler M; Arbeitsgemeinschaft Internistische Onkologie and EXPAND Investigators.

Lancet Oncol. 2013;14(6): 490-9.

Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Oba K, Paoletti X, Bang YJ, Bleiberg H, Burzykowski T, Fuse N, Michiels S, Morita S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, **Kanzler S**, Sargent D, Sasako M, Shitara K, Tsuburaya A, Van Cutsem E, Buyse M. *Eur J Cancer*. 2013 May;49: 1565-77.

Aktueller Stand der diagnostischen Minilaparoskopie für den Hepato-/Gastroenterologen.

Heer A, **Kanzler S**.

*Journal für gastroenterologische und hepatologische Erkrankungen*. 2013; 11.

Erythropoietin treatment in chemotherapy-induced anemia in previously untreated advanced esophagogastric cancer patients.

Thomaidis T, Weinmann A, Sprinzl M, **Kanzler S**, Raedle J, Ebert M, Schimanski CC, Galle PR, Hoehler T, Moehler M; The Upper-GI-Group of AIO (Arbeitsgemeinschaft Internistische Onkologie), Germany. *Int J Clin Oncol*. 2013 Mar 27.

SOCS1 cooperates with FLT3-ITD in the development of myeloproliferative disease by promoting the escape from external cytokine control.

Reddy PN, Sargin B, Choudhary C, Stein S, Grez M, Müller-Tidow C, **Kanzler S**, Berdel WE, Serve H, Brandts CH; Study Alliance Leukemia (SAL). *Blood*. 2012 Aug 23;120: 1691-702.

LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial.

Schimanski CC, Möhler M, Schön M, van Cutsem E, Greil R, Bechstein WO, Hegewisch-Becker S, von Wichert G, Vöhringer M, Heike M, Heinemann V, Peeters M, **Kanzler S**, Kasper S, Overkamp F, Schröder J, Seehofer D, Kullmann F, Linz B, Schmidtmann I, Smith-Machnow V, Gockel I, Lang H, Galle PR. *BMC Cancer*. 2012 Apr 11;12:144.

Liver-specific overexpression of matrix metalloproteinase 9 (MMP-9) in transgenic mice accelerates development of hepatocellular carcinoma.

Thieringer FR, Maass T, Anthon B, Meyer E, Schirmacher P, Longerich T, Galle PR, **Kanzler S**, Teufel A. *Mol Carcinog*. 2012 Jun;51(6):439-48.

[German S3-guideline "Diagnosis and treatment of esophagogastric cancer"].

Moehler M, Al-Batran SE, Andus T, Anthuber M, Arends J, Arnold D, Aust D, Baier P, Baretton G, Bernhardt J, Boeing H, Böhle E, Bokemeyer C, Bornschein J, Budach W, Burmester E, Caca K, Diemer WA, Dietrich CF, Ebert M, Eickhoff A, Ell C, Fahlke J, Feussner H, Fietkau R, Fischbach W, Fleig W, Flentje M, Gabbert HE, Galle PR, Geissler M, Gockel I, Graeven U, Grenacher L, Gross S, Hartmann JT, Heike M, Heinemann V, Herbst B, Herrmann T, Höcht S, Hofheinz RD, Höfler H, Höhler T, Hölscher AH, Horneber M, Hübner J, Izbicki JR, Jakobs R, Jenssen C, **Kanzler S**, Keller M, Kiesslich R, Klautke G, Körber J, Krause BJ, Kuhn C, Kullmann F, Lang H, Link H, Lordick F, Ludwig K, Lutz M, Mahlberg R, Malfertheiner P, Merkel S, Messmann H, Meyer HJ, Mönig S, Piso P, Pistorius S, Porschen R, Rabenstein T, Reichardt P, Ridwelski K, Röcken C, Roetzer I, Rohr P, Schepp W, Schlag PM, Schmid RM, Schmidberger H, Schmiegel WH, Schmol HJ, Schuch G, Schuhmacher C, Schütte K, Schwenk W, Selgrad M, Sendler A, Seraphin J, Seufferlein T, Stahl M, Stein H, Stoll C, Stuschke M, Tannapfel A, Tholen R, Thuss-Patience P, Tremel K, Vanhoefler U, Vieth M, Vogelsang H, Wagner D, Wedding U, Weimann A, Wilke H, Wittekind C; AWMF. *Z Gastroenterol*. 2011 Apr;49(4):461-531. Epub 2011 Apr 7. German. No abstract available.

[Endoscopic ultrasonography-guided fine-needle aspiration (EUS-FNA) as primary diagnostic tool for unclear lesions in the upper gastrointestinal tract].

Moehler M, Voigt J, Kastor M, Heil M, Sengespeick C, Biesterfeld S, Dippold W, **Kanzler S**, Galle PR. *Dtsch Med Wochenschr*. 2011 Feb;136(7):303-8. Epub 2011 Feb 7. German.

Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study.

Moehler M, Mueller A, Trarbach T, Lordick F, Seufferlein T, Kubicka S, Geissler M, Schwarz S, Galle PR, **Kanzler S**; German Arbeitsgemeinschaft Internistische Onkologie. *Ann Oncol*. 2011 Jun;22(6):1358-66. Epub 2010 Nov 30.

Liver-specific Ldb1 deletion results in enhanced liver cancer development.

Teufel A, Maass T, Strand S, **Kanzler S**, Galante T, Becker K, Strand D, Biesterfeld S, Westphal H, Galle PR.

*J Hepatol*. 2010 Dec;53(6):1078-84. Epub 2010 Aug 11.

Liver specific overexpression of platelet-derived growth factor-B accelerates liver cancer development in chemically induced liver carcinogenesis.

Maass T, Thieringer FR, Mann A, Longerich T, Schirmacher P, Strand D, Hansen T, Galle PR, Teufel A, **Kanzler S**.

*Int J Cancer*. 2011 Mar 15;128(6):1259-68. doi: 10.1002/ijc.25469.

Concurrent autoimmune diseases in patients with autoimmune hepatitis.  
Teufel A, Weinmann A, Kahaly GJ, Centner C, Piendl A, Wörns M, Lohse AW, Galle PR, **Kanzler S**.  
J Clin Gastroenterol. 2010 Mar;44(3):208-13.

Related citations

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer.

Trarbach T, Moehler M, Heinemann V, Köhne CH, Przyborek M, Schulz C, Sneller V, Gallant G, **Kanzler S**.

Br J Cancer. 2010 Feb 2;102(3):506-12. Epub 2010 Jan 12.

A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction.

Moehler M, **Kanzler S**, Geissler M, Raedle J, Ebert MP, Daum S, Flieger D, Seufferlein T, Galle PR, Hoehler T; Arbeitsgemeinschaft Internistische Onkologie, Germany.

Ann Oncol. 2010 Jan;21(1):71-7. Epub 2009 Jul 15.

Update on autoimmune hepatitis.

Teufel A, Galle PR, **Kanzler S**.

World J Gastroenterol. 2009 Mar 7;15(9):1035-41. Review.

Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.

Wörns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, Teufel A, Schuchmann M, **Kanzler S**, Düber C, Otto G, Galle PR.

J Clin Gastroenterol. 2009 May-Jun;43(5):489-95.

Hepatocellular carcinoma in patients with autoimmune hepatitis.

Teufel A, Weinmann A, Centner C, Piendl A, Lohse AW, Galle PR, **Kanzler S**.

World J Gastroenterol. 2009 Feb 7;15(5):578-82.

Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients.

Moehler M, Sprinzl MF, Abdelfattah M, Schimanski CC, Adami B, Godderz W, Majer K, Flieger D, Teufel A, Siebler J, Hoehler T, Galle PR, **Kanzler S**.

World J Gastroenterol. 2009 Jan 28;15(4):449-56.

IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53.

Herzer K, Hofmann TG, Teufel A, Schimanski CC, Moehler M, **Kanzler S**, Schulze-Bergkamen H, Galle PR.

Cancer Res. 2009 Feb 1;69(3):855-62. Epub 2009 Jan 13.

A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer.

Mihaljevic A, Büchler P, Harder J, Hofheinz R, Gregor M, **Kanzler S**, Schmiegel W, Heinemann V, Endlicher E, Klöppel G, Seufferlein T, Geissler M.

BMC Surg. 2009 Jan 8;9:1.

Mycophenolate mofetil as second line therapy in autoimmune hepatitis?

Hnnes EM, Oo YH, Schramm C, Denzer U, Buggisch P, Wiegand C, **Kanzler S**, Schuchmann M, Boecher W, Galle PR, Adams DH, Lohse AW.

Am J Gastroenterol. 2008 Dec;103(12):3063-70. Epub 2008 Oct 3.

Characteristics and long-term prognosis of the autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome.

Lüth S, **Kanzler S**, Frenzel C, Kasper HU, Dienes HP, Schramm C, Galle PR, Herkel J, Lohse AW.

J Clin Gastroenterol. 2009 Jan;43(1):75-80.

Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis.

Lüth S, Herkel J, **Kanzler S**, Frenzel C, Galle PR, Dienes HP, Schramm C, Lohse AW.

J Clin Gastroenterol. 2008 Sep;42(8):926-30.

Transforming growth factor-beta-mediated tumor necrosis factor-related apoptosis-inducing ligand expression and apoptosis in hepatoma cells requires functional cooperation between Smad proteins and activator protein-1.

Herzer K, Grosse-Wilde A, Krammer PH, Galle PR, **Kanzler S**.

Mol Cancer Res. 2008 Jul;6(7):1169-77.

In vivo confocal laser endomicroscopy of the human liver: a novel method for assessing liver microarchitecture in real time.  
Goetz M, Kiesslich R, Dienes HP, Drebber U, Murr E, Hoffman A, **Kanzler S**, Galle PR, Delaney P, Neurath MF.  
Endoscopy. 2008 Jul;40(7):554-62.

Hepatocyte-specific Smad7 expression attenuates TGF-beta-mediated fibrogenesis and protects against liver damage.  
Dooley S, Hamzavi J, Ciucian L, Godoy P, Ilkavets I, Ehnert S, Ueberham E, Gebhardt R, **Kanzler S**, Geier A, Breitkopf K, Weng H, Mertens PR.  
Gastroenterology. 2008 Aug;135(2):642-59. Epub 2008 May 15.

Spontaneous hepatic fibrosis in transgenic mice overexpressing PDGF-A.  
Thieringer F, Maass T, Czochra P, Klopčič B, Conrad I, Friebe D, Schirmacher P, Lohse AW, Blessing M, Galle PR, Teufel A, **Kanzler S**.  
Gene. 2008 Oct 15;423(1):23-8. Epub 2008 Jun 10.

Improved scatterer size estimation using backscatter coefficient measurements with coded excitation and pulse compression.  
Kanzler SG, Oelze ML.  
J Acoust Soc Am. 2008 Jun;123(6):4599-607.

PDGFRalpha/beta expression correlates with the metastatic behavior of human colorectal cancer: a possible rationale for a molecular targeting strategy.  
Wehler TC, Frerichs K, Graf C, Drescher D, Schimanski K, Biesterfeld S, Berger MR, **Kanzler S**, Junginger T, Galle PR, Moehler M, Gockel I, Schimanski CC.  
Oncol Rep. 2008 Mar;19(3):697-704.

In vivo confocal laser laparoscopy allows real time subsurface microscopy in animal models of liver disease.  
Goetz M, Vieth M, **Kanzler S**, Galle PR, Delaney P, Neurath MF, Kiesslich R.  
J Hepatol. 2008 Jan;48(1):91-7. Epub 2007 Oct 2.

Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases.  
Wörns MA, Teufel A, **Kanzler S**, Shrestha A, Victor A, Otto G, Lohse AW, Galle PR, Höhler T.  
Am J Gastroenterol. 2008 Jan;103(1):138-46. Epub 2007 Oct 26.

[Transarterial chemoembolization (TACE) of the hepatocellular carcinoma (HCC) in patients with portal vein thrombosis--experiences].  
Herber S, Pitton M, Mönch C, Schneider J, Manzl N, Kummer I, **Kanzler S**, Schuchmann M, Junginger T, Düber C, Otto G.  
Zentralbl Chir. 2007 Aug;132(4):306-15. German.

[Liver metastases of colorectal carcinoma--how often can be operated upon?].  
Junginger T, Kneist W, Dünschede F, von Langsdorff C, Seifert J, **Kanzler S**.  
Zentralbl Chir. 2007 Aug;132(4):281-6. German.

[Liver function test to predict hepatic failure after liver resection--expensive and without clinical relevance?].  
**Kanzler S**, Teufel A, Galle PR.  
Zentralbl Chir. 2007 Aug;132(4):267-73. Review. German.

Profibrogenic transforming growth factor-beta/activin receptor-like kinase 5 signaling via connective tissue growth factor expression in hepatocytes.  
Weng HL, Ciucian L, Liu Y, Hamzavi J, Godoy P, Gaitantzi H, **Kanzler S**, Heuchel R, Ueberham U, Gebhardt R, Breitkopf K, Dooley S.  
Hepatology. 2007 Oct;46(4):1257-70.

Genetics of hepatocellular carcinoma.  
Teufel A, Staib F, **Kanzler S**, Weinmann A, Schulze-Bergkamen H, Galle PR.  
World J Gastroenterol. 2007 Apr 28;13(16):2271-82. Review.

Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma.  
Herber S, Otto G, Schneider J, Manzl N, Kummer I, **Kanzler S**, Schuchmann A, Thies J, Düber C, Pitton M.  
Cardiovasc Intervent Radiol. 2007 Nov-Dec;30(6):1156-65. Epub 2007 May 17.

Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.

Zimmermann T, Böcher WO, Biesterfeld S, Zimmermann A, **Kanzler S**, Greif-Higer G, Barreiros AP, Sprinzl MF, Wörns MA, Lohse AW, Mönch C, Otto G, Galle PR, Schuchmann M. Transpl Int. 2007 Jul;20(7):583-90. Epub 2007 Apr 13.

In-vivo confocal real-time mini-microscopy in animal models of human inflammatory and neoplastic diseases.

Goetz M, Fottner C, Schirmacher E, Delaney P, Gregor S, Schneider C, Strand D, **Kanzler S**, Memadathil B, Weyand E, Holtmann M, Schirmacher R, Weber MM, Anlauf M, Klöppel G, Vieth M, Galle PR, Bartenstein P, Neurath MF, Kiesslich R. Endoscopy. 2007 Apr;39(4):350-6.

[Single center experience over a 5-year period with sequential transarterial chemoembolization (TACE) in the treatment of hepatocellular carcinoma (HCC)].

Herber SC, Otto G, Woerns M, Moench C, **Kanzler S**, Junginger T, Schneider J, Schuchmann M, Kummer I, Manzl N, Düber C, Pitton MB. Rofo. 2007 Mar;179(3):289-99. German.

Prospective randomized comparison of minilaparoscopy and percutaneous liver biopsy: diagnosis of cirrhosis and complications.

Denzer U, Arnoldy A, **Kanzler S**, Galle PR, Dienes HP, Lohse AW. J Clin Gastroenterol. 2007 Jan;41(1):103-10.

[Massive hemorrhage in a 28-year-old male patient with intestinal Behçet's disease].

Waldner M, Schimanski C, Klaas W, Bittinger F, Pitton M, Korenkov M, Kiesslich R, Neurath M, Galle P, **Kanzler S**. Z Gastroenterol. 2006 Oct;44(10):1047-51. German.

Genetic association of autoimmune hepatitis and human leucocyte antigen in German patients.

Teufel A, Wörns M, Weinmann A, Centner C, Piendl A, Lohse AW, Galle PR, **Kanzler S**. World J Gastroenterol. 2006 Sep 14;12(34):5513-6.

[Immunotherapy of colorectal cancer--overview and perspectives].

Schimanski CC, Hörner V, **Kanzler S**, Galle PR, Moehler M. Z Gastroenterol. 2006 Aug;44(8):673-81. Review. German.

Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report.

Sprinzl MF, Schimanski CC, Moehler M, Schadmand-Fischer S, Galle PR, **Kanzler S**. BMC Cancer. 2006 Jul 17;6:190.

Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice.

Czochra P, Klopčič B, Meyer E, Herkel J, Garcia-Lazaro JF, Thieringer F, Schirmacher P, Biesterfeld S, Galle PR, Lohse AW, **Kanzler S**. J Hepatol. 2006 Sep;45(3):419-28. Epub 2006 May 30.

Five cases of de novo inflammatory bowel disease after orthotopic liver transplantation.

Wörns MA, Lohse AW, Neurath MF, Croxford A, Otto G, Kreft A, Galle PR, **Kanzler S**. Am J Gastroenterol. 2006 Aug;101(8):1931-7. Epub 2006 Jun 22.

Pregnancy in autoimmune hepatitis: outcome and risk factors.

Schramm C, Herkel J, Beuers U, **Kanzler S**, Galle PR, Lohse AW. Am J Gastroenterol. 2006 Mar;101(3):556-60. Epub 2006 Feb 8.

Budesonide in previously untreated autoimmune hepatitis.

Wiegand J, Schüler A, **Kanzler S**, Lohse A, Beuers U, Kreisel W, Spengler U, Koletzko S, Jansen PL, Hochhaus G, Möllmann HW, Pröls M, Manns MP. Liver Int. 2005 Oct;25(5):927-34.

[Combined simulation training: a new concept and workshop is useful for crisis management in gastrointestinal endoscopy].

Kiesslich R, Moenk S, Reinhardt K, **Kanzler S**, Schilling D, Jakobs R, Denzer U, Neumann M, Vollmer J, Schütz M, Heinrichs W, Neurath MF, Galle PR. Z Gastroenterol. 2005 Sep;43(9):1031-9. German.

Hepatic over-expression of TGF-beta1 promotes LPS-induced inflammatory cytokine secretion by liver cells and endotoxemic shock.

Garcia-Lazaro JF, Thieringer F, Lüth S, Czochra P, Meyer E, Renteria IB, Galle PR, Lohse AW, Herkel J, **Kanzler S**. Immunol Lett. 2005 Nov 15;101(2):217-22.

Prospective comparison of cardiopulmonary events during minilaparoscopy and colonoscopy under conscious sedation.

Denzer U, Mollenhauer M, **Kanzler S**, Galle PR, Lohse AW.  
Endoscopy. 2005 May;37(5):460-5.

Current practice in managing patients on anticoagulants and/or antiplatelet agents around the time of gastrointestinal endoscopy -- a nation-wide survey in Germany.

Mosler P, Mergener K, Denzer U, Kiesslich R, Galle PR, **Kanzler S**.  
Z Gastroenterol. 2004 Nov;42(11):1289-93.

Minimal change esophagitis: prospective comparison of endoscopic and histological markers between patients with non-erosive reflux disease and normal controls using magnifying endoscopy.

Kiesslich R, **Kanzler S**, Vieth M, Moehler M, Neidig J, Thanka Nadar BJ, Schilling D, Burg J, Nafe B, Neurath MF, Galle PR.  
Dig Dis. 2004;22(2):221-7.

Phenprocoumon-induced liver disease ranges from mild acute hepatitis to (sub-) acute liver failure.

Schimanski CC, Burg J, Möhler M, Höhler T, **Kanzler S**, Otto G, Galle PR, Lohse AW.

J Hepatol. 2004 Jul;41(1):67-74.

Minilaparoscopy in the diagnosis of peritoneal tumor spread: prospective controlled comparison with computed tomography.

Denzer U, Hoffmann S, Helmreich-Becker I, Kauczor HU, Thelen M, **Kanzler S**, Galle PR, Lohse AW.  
Surg Endosc. 2004 Jul;18(7):1067-70. Epub 2004 May 27.

[Autoimmune liver disease: diagnosis and therapy].

Bayer EM, Schramm C, **Kanzler S**, Lohse AW.  
Z Gastroenterol. 2004 Jan;42(1):19-30. Review. German.

Use of a duodenoscope in the management of a ureteral calculus in a patient with ureterosigmoidostomy (Mainz pouch II; rectosigmoid pouch).

Mosler P, Kiesslich R, Stein R, Galle PR, Thüroff JW, **Kanzler S**.  
Endoscopy. 2003 Dec;35(12):1086-7. No abstract available.

Mini-laparoscopically guided percutaneous gastrostomy and jejunostomy.

Denzer U, Mergener K, **Kanzler S**, Kiesslich R, Helmreich-Becker I, Galle PR, Lohse AW.  
Gastrointest Endosc. 2003 Sep;58(3):434-8.

Value of chromoendoscopy and magnification endoscopy in the evaluation of duodenal abnormalities: a prospective, randomized comparison.

Kiesslich R, Mergener K, Naumann C, Hahn M, Jung M, Koehler HH, Nafe B, **Kanzler S**, Galle PR.  
Endoscopy. 2003 Jul;35(7):559-63.

Prevalence of autoantibodies to the p53 protein in autoimmune hepatitis.

Herkel J, Modrow JP, Bamberger S, **Kanzler S**, Rotter V, Cohen IR, Lohse AW.  
Autoimmunity. 2002 Dec;35(8):493-6.

MHC class II-expressing hepatocytes function as antigen-presenting cells and activate specific CD4 T lymphocytes.

Herkel J, Jagemann B, Wiegand C, Lazaro JF, Lueth S, **Kanzler S**, Blessing M, Schmitt E, Lohse AW.  
Hepatology. 2003 May;37(5):1079-85.

Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis.

Kiesslich R, Fritsch J, Holtmann M, Koehler HH, Stolte M, **Kanzler S**, Nafe B, Jung M, Galle PR, Neurath MF.  
Gastroenterology. 2003 Apr;124(4):880-8.

[Apoptosis in disease].

Schuchmann M, Galle PR, **Kanzler S**.  
Med Klin (Munich). 2002 Dec 15;97(12):738-46. Review. German.

Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics.

Baeres M, Herkel J, Czaja AJ, Wies I, **Kanzler S**, Cancado EL, Porta G, Nishioka M, Simon T, Daehnrich C, Schlumberger W, Galle PR, Lohse AW.  
Gut. 2002 Aug;51(2):259-64.

Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta.

**Kanzler S**, Baumann M, Schirmacher P, Dries V, Bayer E, Gerken G, Dienes HP, Lohse AW. J Viral Hepat. 2001 Nov;8(6):430-7.

Hepatocellular expression of a dominant-negative mutant TGF-beta type II receptor accelerates chemically induced hepatocarcinogenesis.

**Kanzler S**, Meyer E, Lohse AW, Schirmacher P, Henninger J, Galle PR, Blessing M. Oncogene. 2001 Aug 16;20(36):5015-24.

Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience.

**Kanzler S**, Löhr H, Gerken G, Galle PR, Lohse AW. Z Gastroenterol. 2001 May;39(5):339-41, 344-8.

Autoimmune hepatitis in the elderly.

Schramm C, **Kanzler S**, zum Büschenfelde KH, Galle PR, Lohse AW. Am J Gastroenterol. 2001 May;96(5):1587-91.

[Presence of SLA/LP autoantibodies in patients with primary biliary cirrhosis as a marker for secondary autoimmune hepatitis (overlap syndrome)].

**Kanzler S**, Bozkurt S, Herkel J, Galle PR, Dienes HP, Lohse AW. Dtsch Med Wochenschr. 2001 Apr 20;126(16):450-6. German.

Duration of immunosuppressive therapy in autoimmune hepatitis.

**Kanzler S**, Gerken G, Löhr H, Galle PR, Meyer zum Büschenfelde KH, Lohse AW. J Hepatol. 2001 Feb;34(2):354-5. No abstract available.

Hemobilia after minilaparoscopic liver biopsy: a rare complication.

Moehler M, Sanwald B, **Kanzler S**, Wanitschke R, Galle PR, Helmreich-Becker I. Endoscopy. 2000 Sep;32(9):S60. No abstract available.

How long to treat chronic hepatitis B virus infection with lamivudine?

Löhr HF, Schlaak JF, Lohse AW, Böcher WO, **Kanzler S**, Ibe M, Galle PR. J Hepatol. 2000 Aug;33(2):343. No abstract available.

Apoptosis and the liver.

**Kanzler S**, Galle PR. Semin Cancer Biol. 2000 Jun;10(3):173-84. Review.

A novel class of aromatic vitamin D analogs.

Rodriguez DS, **Kanzler S**, Reischl W, Zorgdrager J, Halkes S, van de Velde JP. Curr Pharm Des. 2000 May;6(7):749-54.

Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis.

Wies I, Brunner S, Henninger J, Herkel J, **Kanzler S**, Meyer zum Büschenfelde KH, Lohse AW. Lancet. 2000 Apr 29;355(9214):1510-5.

Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis.

**Kanzler S**, Weidemann C, Gerken G, Löhr HF, Galle PR, Meyer zum Büschenfelde KH, Lohse AW. J Hepatol. 1999 Oct;31(4):635-40.

TGF-beta1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis.

**Kanzler S**, Lohse AW, Keil A, Henninger J, Dienes HP, Schirmacher P, Rose-John S, zum Büschenfelde KH, Blessing M. Am J Physiol. 1999 Apr;276(4 Pt 1):G1059-68.

Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatic form of PBC in genetically susceptible individuals.

Lohse AW, zum Büschenfelde KH, Franz B, **Kanzler S**, Gerken G, Dienes HP. Hepatology. 1999 Apr;29(4):1078-84.

Cutting edge: chronic intestinal inflammation in STAT-4 transgenic mice: characterization of disease and adoptive transfer by TNF- plus IFN-gamma-producing CD4+ T cells that respond to bacterial antigens.

Wirtz S, Finotto S, **Kanzler S**, Lohse AW, Blessing M, Lehr HA, Galle PR, Neurath MF. J Immunol. 1999 Feb 15;162(4):1884-8.

Transforming growth factor-beta1 in autoimmune hepatitis: correlation of liver tissue expression and serum levels with disease activity.

Bayer EM, Herr W, **Kanzler S**, Waldmann C, Meyer Zum Büschenfelde KH, Dienes HP, Lohse AW. J Hepatol. 1998 May;28(5):803-11.

Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis--report of three cases.

**Kanzler S**, Gerken G, Dienes HP, Meyer zum Büschenfelde KH, Lohse AW.  
Z Gastroenterol. 1997 Jul;35(7):571-8.

Autoimmune findings resembling connective tissue disease in a patient with Castleman's disease.

Gohlke F, Märker-Hermann E, **Kanzler S**, Mitze M, Meyer zum Büschenfelde KH.  
Clin Rheumatol. 1997 Jan;16(1):87-92. Review.

Complete reversal of FK 506 induced diabetes in a liver transplant recipient by change of immunosuppression to cyclosporine A.

**Kanzler S**, Lohse AW, Schirmacher P, Hermann E, Otto G, Meyer zum Büschenfelde KH.  
Z Gastroenterol. 1996 Feb;34(2):128-31.

[Therapy refractory atypical polyarthritis and cryoglobulinemia in a patient with colon carcinoma and palliative intestinal bypass. Differential diagnosis: carcinoma-polyarthritis or bypass arthritis].

**Kanzler S**, Gohlke F, Meyer Zum Büschenfelde KH, Märker-Hermann E.  
Z Gastroenterol. 1995 Aug;33(8):449-53. German.